[go: up one dir, main page]

CY1123702T1 - Πυραζολο[1,5-αλφα]πυριμιδινες χρησιμες ως αναστολεις της κινασης atr για την αντιμετωπιση καρκινικων νοσων - Google Patents

Πυραζολο[1,5-αλφα]πυριμιδινες χρησιμες ως αναστολεις της κινασης atr για την αντιμετωπιση καρκινικων νοσων

Info

Publication number
CY1123702T1
CY1123702T1 CY20201101212T CY201101212T CY1123702T1 CY 1123702 T1 CY1123702 T1 CY 1123702T1 CY 20201101212 T CY20201101212 T CY 20201101212T CY 201101212 T CY201101212 T CY 201101212T CY 1123702 T1 CY1123702 T1 CY 1123702T1
Authority
CY
Cyprus
Prior art keywords
compounds
kinase inhibitors
pyrazolo
pyrimidines
usable
Prior art date
Application number
CY20201101212T
Other languages
English (en)
Inventor
Nadia AHMAD
Dean Boyall
Jean-Damien Charrier
Chris Davis
Rebecca Davis
Steven Durrant
Gorka ETXEBARRIA I JARDI
Damine FRAYSSE
Juan-Miguel Jimenez
David Kay
Ronald Knegtel
Donald Middleton
Michael ODONNELL
Maninder PANESAR
Francoise Pierard
Joanne Pinder
David Shaw
Pierre-Henri Storck
John Studley
Heather Twin
Original Assignee
Vertex Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc. filed Critical Vertex Pharmaceuticals Inc.
Publication of CY1123702T1 publication Critical patent/CY1123702T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε ενώσεις χρήσιμες ως αναστολείς κινάσης πρωτεΐνης ATR. Η εφεύρεση αναφέρεται, επίσης, σε φαρμακευτικώς αποδεκτές συνθέσεις, οι οποίες περιέχουν τις ενώσεις αυτής της εφεύρεσης• μεθόδους θεραπευτικής αγωγής διαφόρων ασθενειών, διαταραχών και καταστάσεων με χρήση των ενώσεων αυτής της εφεύρεσης• ενδιάμεσα για την παρασκευή των ενώσεων αυτής της εφεύρεσης• και μεθόδους χρήσης των ενώσεων σε in vitro εφαρμογές, όπως η μελέτη κινασών σε βιολογικά και παθολογικά φαινόμενα• η μελέτη οδών μεταγωγής ενδοκυτταρικών σημάτων που διαμεσολαβούνται από τέτοιες κινάσες• και τη συγκριτική αξιολόγηση νέων αναστολέων κινασών. Οι ενώσεις αυτής της εφεύρεσης έχουν τον τύπο (Ι) ή ένα φαρμακευτικώς αποδεκτό άλας, όπου οι μεταβλητές είναι όπως ορίζονται στο παρόν. Επιπλέον, οι ενώσεις αυτής της εφεύρεσης έχουν τύπο (Ι-Α) ή ένα φαρμακευτικώς αποδεκτό άλας, όπου οι μεταβλητές είναι όπως ορίζονται στο παρόν.
CY20201101212T 2012-12-07 2020-12-23 Πυραζολο[1,5-αλφα]πυριμιδινες χρησιμες ως αναστολεις της κινασης atr για την αντιμετωπιση καρκινικων νοσων CY1123702T1 (el)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261734726P 2012-12-07 2012-12-07
US201361787568P 2013-03-15 2013-03-15
US201361868132P 2013-08-21 2013-08-21
PCT/US2013/073457 WO2014089379A1 (en) 2012-12-07 2013-12-06 Compounds useful as inhibitors of atr kinase
EP13811716.3A EP2941432B8 (en) 2012-12-07 2013-12-06 2-amino-6-fluoro-n-(5-fluoro-4-(4-(4-(oxetan-3-yl)piperazine-1-carbonyl)piperidin-1-yl)pyridin-3-yl)pyrazolo[1,5alpha]pyrimidine-3-carboxamide as inhibitor of atr kinase

Publications (1)

Publication Number Publication Date
CY1123702T1 true CY1123702T1 (el) 2022-03-24

Family

ID=49877035

Family Applications (4)

Application Number Title Priority Date Filing Date
CY20181100515T CY1120232T1 (el) 2012-12-07 2018-05-18 2-αμινο-6-φθορο-ν-(5-φθορο-4-(4-(4-(οξεταν-3-υλ)πιπεραζινο-1-καρβονυλ)πιπεριδιν-1-υλ)πυριδιν-3-υλ)πυραζολο[1,5αλφα]πυριμιδινο-3-καρβοξαμιδιο ως αναστολεας κινασης atr
CY20201101212T CY1123702T1 (el) 2012-12-07 2020-12-23 Πυραζολο[1,5-αλφα]πυριμιδινες χρησιμες ως αναστολεις της κινασης atr για την αντιμετωπιση καρκινικων νοσων
CY20211100593T CY1124291T1 (el) 2012-12-07 2021-07-02 2-αμινο-ν-(πιπεριδιν-1-υλ-πυριδιν-3-υλ)πυραzολο[1,5αλφα] πυριμιδινη-3-καρβοξαμιδιο ως αναστολεας της atr κινασης
CY20231100238T CY1126044T1 (el) 2012-12-07 2023-05-18 Πυραζολο[1,5-αλφα]πυριμιδινες χρησιμες ως αναστολεις της κινασης atr για την αντιμετωπιση καρκινικων νοσων

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20181100515T CY1120232T1 (el) 2012-12-07 2018-05-18 2-αμινο-6-φθορο-ν-(5-φθορο-4-(4-(4-(οξεταν-3-υλ)πιπεραζινο-1-καρβονυλ)πιπεριδιν-1-υλ)πυριδιν-3-υλ)πυραζολο[1,5αλφα]πυριμιδινο-3-καρβοξαμιδιο ως αναστολεας κινασης atr

Family Applications After (2)

Application Number Title Priority Date Filing Date
CY20211100593T CY1124291T1 (el) 2012-12-07 2021-07-02 2-αμινο-ν-(πιπεριδιν-1-υλ-πυριδιν-3-υλ)πυραzολο[1,5αλφα] πυριμιδινη-3-καρβοξαμιδιο ως αναστολεας της atr κινασης
CY20231100238T CY1126044T1 (el) 2012-12-07 2023-05-18 Πυραζολο[1,5-αλφα]πυριμιδινες χρησιμες ως αναστολεις της κινασης atr για την αντιμετωπιση καρκινικων νοσων

Country Status (31)

Country Link
US (8) US9340546B2 (el)
EP (6) EP4190786B1 (el)
JP (2) JP6401709B2 (el)
KR (1) KR102213986B1 (el)
CN (4) CN107501274B (el)
AU (2) AU2013355124B2 (el)
BR (1) BR112015012454B1 (el)
CA (1) CA2892608C (el)
CY (4) CY1120232T1 (el)
DK (4) DK3808749T3 (el)
ES (4) ES2669423T3 (el)
FI (1) FI3808749T3 (el)
HK (2) HK1209746A1 (el)
HR (4) HRP20230476T1 (el)
HU (4) HUE052808T2 (el)
IL (2) IL239218A0 (el)
LT (4) LT3418281T (el)
ME (1) ME03036B (el)
MX (1) MX368042B (el)
NZ (2) NZ630457A (el)
PL (3) PL2941432T3 (el)
PT (4) PT3808749T (el)
RS (4) RS57210B1 (el)
RU (1) RU2689996C2 (el)
SG (2) SG10201606373XA (el)
SI (4) SI3808749T1 (el)
SM (4) SMT202000713T1 (el)
TR (1) TR201807740T4 (el)
TW (1) TWI618706B (el)
WO (1) WO2014089379A1 (el)
ZA (2) ZA201503871B (el)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20220581T1 (hr) 2008-12-19 2022-06-10 Vertex Pharmaceuticals Incorporated Spojevi korisni kao inhibitori atr kinaze
WO2012178125A1 (en) 2011-06-22 2012-12-27 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
CN103957917A (zh) 2011-09-30 2014-07-30 沃泰克斯药物股份有限公司 用atr抑制剂治疗胰腺癌和非小细胞肺癌
EP2751097A2 (en) 2011-09-30 2014-07-09 Vertex Pharmaceuticals Incorporated Processes for making compounds useful as inhibitors of atr kinase
NZ726671A (en) 2012-04-05 2018-04-27 Vertex Pharma Compounds useful as inhibitors of atr kinase and combination therapies thereof
RS57210B1 (sr) 2012-12-07 2018-07-31 Vertex Pharmaceuticals Inncorporated 2-amino-6-fluoro-n-(5-fluoro-4-(4-(4-(oksetan-3-il)piperazin-1-karbonil)piperidin-1-il)piridin-3-il)pirazolo[1,5alfa]pirimidin-3-karboksamid kao inhibitor atr kinaze
WO2014110574A1 (en) 2013-01-14 2014-07-17 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
WO2014113388A1 (en) 2013-01-15 2014-07-24 Incyte Corporation Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors
US8957078B2 (en) 2013-03-15 2015-02-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
EP2970286A1 (en) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Inc. Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
JP2016512816A (ja) 2013-03-15 2016-05-09 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼの阻害剤として有用な化合物
CN105658653A (zh) * 2013-08-23 2016-06-08 因赛特公司 可用作pim激酶抑制剂的呋喃并-和噻吩并-吡啶甲酰胺化合物
RU2720408C2 (ru) * 2013-12-06 2020-04-29 Вертекс Фармасьютикалз Инкорпорейтед Способ получения ингибиторов atr киназы (варианты)
ES2777608T3 (es) 2014-06-05 2020-08-05 Vertex Pharma Derivados radiomarcados de un compuesto de 2-amino-6-fluoro-N-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida útiles como inhibidores de ATR cinasa, la preparación de dicho compuesto y diferentes formas sólidas del mismo
NZ727399A (en) 2014-06-17 2022-07-29 Vertex Pharma Method for treating cancer using a combination of chk1 and atr inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
TWI656121B (zh) 2014-08-04 2019-04-11 德商拜耳製藥公司 ２－（嗎啉－４－基）－１，７－萘啶
ES2838573T3 (es) * 2014-08-21 2021-07-02 Bristol Myers Squibb Co Derivados de benzamida ligados como inhibidores potentes de ROCK
WO2016073889A1 (en) 2014-11-06 2016-05-12 Lysosomal Therapeutics Inc. Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders
AU2015342883B2 (en) 2014-11-06 2020-07-02 Bial - R&D Investments, S.A. Substituted pyrrolo(1,2-a)pyrimidines and their use in the treatment of medical disorders
SMT202400187T1 (it) * 2014-11-06 2024-07-09 Bial R&D Investments S A Pirazolo(1,5-a)pirimidine sostituite e loro utilizzo nel trattamento di disturbi medici
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
MX395066B (es) 2015-09-30 2025-03-24 Vertex Pharma Método para tratar cáncer usando una combinación de agentes que dañan el adn e inhibidores de proteína relacionada con ataxia telangiectasia y rad3 (atr).
US9920032B2 (en) 2015-10-02 2018-03-20 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
JP7560026B2 (ja) * 2016-01-08 2024-10-02 ザ インスティチュート オブ キャンサー リサーチ，ロイヤル キャンサー ホスピタル 癌を治療する方法における使用のための毛細血管拡張性運動失調症の変異したＲａｄ３関連タンパク質キナーゼ（ＡＴＲ）の阻害剤
ES2997263T3 (en) 2016-01-11 2025-02-14 Celator Pharmaceuticals Inc Inhibiting ataxia telangiectasia and rad3-related protein (atr)
RU2018132559A (ru) * 2016-02-16 2020-03-17 Массачусетс Инститьют Оф Текнолоджи Связывающие молекулы для max в качестве модуляторов myc и их применения
US11192892B2 (en) 2016-04-06 2021-12-07 Bial—R&D Investments, S.A. Substituted pyrazolo[1,5-a]pyrimidines for the treatment of medical disorders
EP3440081A4 (en) 2016-04-06 2019-09-18 Lysosomal Therapeutics Inc. PYRROLO [1,2-A] PYRIMIDINYL-CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDER
JP7046827B2 (ja) 2016-04-06 2022-04-04 リソソーマル・セラピューティクス・インコーポレイテッド イミダゾ［１，５－ａ］ピリミジニルカルボキサミド化合物および医学的障害の処置におけるその使用
WO2017192931A1 (en) 2016-05-05 2017-11-09 Lysosomal Therapeutics Inc. SUBSTITUTED IMDAZO[1,2-α]PYRIDINES, SUBSTITUTED IMIDAZO[1,2-α]PYRAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
US11168087B2 (en) 2016-05-05 2021-11-09 Bial—R&D Investments, S.A. Substituted imidazo[1,2-b]pyridazines, substituted imidazo[1,5-b]pyridazines, related compounds, and their use in the treatment of medical disorders
CN109890829B (zh) 2016-11-02 2022-07-15 豪夫迈·罗氏有限公司 作为IRAK4调节剂的吡唑并[1,5a]嘧啶衍生物
JOP20190197A1 (ar) 2017-02-24 2019-08-22 Bayer Pharma AG مثبط كيناز ايه تي آر للاستخدام في طريقة لعلاج مرض فرط التكاثر
WO2018153972A1 (en) 2017-02-24 2018-08-30 Bayer Pharma Aktiengesellschaft Combination of atr kinase inhibitors and antiandrogens
AR110995A1 (es) 2017-02-24 2019-05-22 Bayer Ag Combinación de inhibidores de quinasa atr con sal de radio-223
CN106946890A (zh) * 2017-04-26 2017-07-14 中国药科大学 吡啶类irak4抑制剂、其制备方法及应用
WO2018206547A1 (en) 2017-05-12 2018-11-15 Bayer Pharma Aktiengesellschaft Combination of bub1 and atr inhibitors
EP3630116B1 (en) 2017-05-26 2024-05-01 The Board Of Regents Of The University Of Texas System Tetrahydropyrido[4,3-d]pyrimidine inhibitors of atr kinase
HRP20240368T1 (hr) 2017-07-13 2024-08-30 Board Of Regents, The University Of Texas System Heterociklički inhibitori atr kinaze
LT3658557T (lt) 2017-07-28 2024-09-25 Takeda Pharmaceutical Company Limited Tyk2 inhibitoriai ir jų naudojimas
US11690911B2 (en) 2017-08-04 2023-07-04 Bayer Aktiengesellschaft Combination of ATR kinase inhibitors and PD-1/PD-L1 inhibitors
CN111886224B (zh) 2017-08-17 2024-07-23 德州大学系统董事会 Atr激酶的杂环抑制剂
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
CN107935918A (zh) * 2017-11-15 2018-04-20 山东潍坊润丰化工股份有限公司 一种百草枯的制备方法
EP3717016A4 (en) * 2017-11-30 2021-09-01 Seagen Inc. PROCESS FOR THE PREPARATION OF DRUG COUPLING COMPOUNDS
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
EP3720973A1 (en) 2017-12-08 2020-10-14 Bayer Aktiengesellschaft Predictive markers for atr kinase inhibitors
SG11202005156WA (en) * 2017-12-29 2020-07-29 Vertex Pharma Methods of cancer treatment using an atr inhibitor
CN112218631B (zh) 2018-03-16 2023-12-22 德州大学系统董事会 Atr激酶的杂环抑制剂
JP2022502399A (ja) * 2018-09-26 2022-01-11 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung がんの治療のためのｐｄ−１アンタゴニスト、ａｔｒインヒビター、および白金製剤の組合せ
WO2020078905A1 (en) 2018-10-15 2020-04-23 Merck Patent Gmbh Combination therapy utilizing dna alkylating agents and atr inhibitors
EP3866805A1 (en) 2018-10-16 2021-08-25 Bayer Aktiengesellschaft Combination of atr kinase inhibitors with 2,3-dihydroimidazo[1,2-c]quinazoline compounds
CN112142744A (zh) * 2019-06-28 2020-12-29 上海瑛派药业有限公司 取代的稠合杂芳双环化合物作为激酶抑制剂及其应用
WO2021178832A2 (en) * 2020-03-06 2021-09-10 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Dna damage repair genes in cancer
WO2021187605A1 (ja) * 2020-03-19 2021-09-23 田辺三菱製薬株式会社 含窒素複素環αシアノカルボニル化合物
AU2021291358A1 (en) * 2020-06-18 2022-12-15 Merck Patent Gmbh Compounds for the treatment of viral infections
WO2022002243A1 (zh) * 2020-07-02 2022-01-06 江苏恒瑞医药股份有限公司 咪唑并嘧啶类衍生物、其制备方法及其在医药上的应用
CN116283960A (zh) 2021-12-21 2023-06-23 上海安诺达生物科技有限公司 取代的稠杂环化合物及其制备方法与应用
WO2023116865A1 (zh) * 2021-12-23 2023-06-29 优领医药科技（上海）有限公司 含吡唑类衍生物、其药学上可接受的盐及其制备方法和应用
CN115322143B (zh) * 2022-07-21 2023-07-14 安徽德诺医药股份有限公司 一种4-哌啶甲酸叔丁酯盐酸盐的制备方法
US20250084085A1 (en) 2023-08-01 2025-03-13 Principia Biopharma Inc. Process of making 2-[(3r)-2-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4[4-(oxetan-3-yl)piperazin-1-yl]-pent-2-enenitrile and solvate forms thereof

Family Cites Families (265)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4309430A (en) 1980-06-27 1982-01-05 Merck & Co., Inc. Pyrazinyl-1,2,4-oxadiazole-5-ones, for treatment of edema, and processes for preparing same
US5329012A (en) 1987-10-29 1994-07-12 The Research Foundation Of State University Of New York Bis(acyloxmethyl)imidazole compounds
JP2597917B2 (ja) 1990-04-26 1997-04-09 富士写真フイルム株式会社 新規な色素形成カプラー及びそれを用いたハロゲン化銀カラー写真感光材料
KR19990008451A (ko) 1995-05-09 1999-01-25 페라스타르크 피라졸로-(1,5ａ)-피리미딘, 그의 제조 방법 및 용도
WO1997043267A1 (en) 1996-05-11 1997-11-20 Kings College London Pyrazines
US6060478A (en) 1996-07-24 2000-05-09 Dupont Pharmaceuticals Azolo triazines and pyrimidines
US6191131B1 (en) 1997-07-23 2001-02-20 Dupont Pharmaceuticals Company Azolo triazines and pyrimidines
RO121272B1 (ro) 1996-07-24 2007-02-28 The Du Pont Merck Pharmaceutical Company Azolotriazine şi pirimidine
JPH10218881A (ja) 1997-02-03 1998-08-18 Pola Chem Ind Inc 新規なピロロピラゾロピリミジン誘導体
GB2323861B (en) 1997-02-05 2001-06-20 Sector Exhibiting Systems Artificial wall structure
JP2002241379A (ja) 1997-03-21 2002-08-28 Dainippon Pharmaceut Co Ltd ３−オキサジアゾリルキノキサリン誘導体
JP2002501532A (ja) 1997-05-30 2002-01-15 メルク エンド カンパニー インコーポレーテッド 新規血管形成阻害薬
US6235741B1 (en) 1997-05-30 2001-05-22 Merck & Co., Inc. Angiogenesis inhibitors
CA2336832A1 (en) 1998-07-16 2000-01-27 Shionogi & Co., Ltd. Pyrimidine derivatives exhibiting antitumor activity
US6245759B1 (en) 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
US6660753B2 (en) 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
JP2001302666A (ja) 1999-09-21 2001-10-31 Nissan Chem Ind Ltd アゾール縮合ヘテロ環アニライド化合物及び除草剤
MY125533A (en) 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
EP1237880B1 (en) 1999-12-17 2008-01-23 Novartis Vaccines and Diagnostics, Inc. Pyrazine based inhibitors of glycogen synthase kinase 3
WO2001092257A1 (en) 2000-05-26 2001-12-06 Neurogen Corporation Oxo-imidazopyrimidine-carboxamides and their use as gaba brain receptor ligands
US20020041880A1 (en) 2000-07-05 2002-04-11 Defeo-Jones Deborah Method of treating cancer
US6849660B1 (en) 2000-08-01 2005-02-01 Isis Pharmaceuticals, Inc. Antimicrobial biaryl compounds
US7067520B2 (en) 2000-11-17 2006-06-27 Ishihara Sangyo Kaisha, Ltd. Preventive or therapeutic medicines for diabetes containing fused-heterocyclic compounds or their salts
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
US6420637B1 (en) 2001-01-29 2002-07-16 Asgrow Seed Company L.L.C. Plants and seeds of corn variety I389972
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
US6858600B2 (en) 2001-05-08 2005-02-22 Yale University Proteomimetic compounds and methods
US20030114467A1 (en) 2001-06-21 2003-06-19 Shakespeare William C. Novel pyrazolo- and pyrrolo-pyrimidines and uses thereof
SE0102439D0 (sv) 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
SE0102438D0 (sv) 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
WO2003037900A2 (en) 2001-11-01 2003-05-08 Icagen, Inc. Pyrazolopyrimidines
US6992087B2 (en) 2001-11-21 2006-01-31 Pfizer Inc Substituted aryl 1,4-pyrazine derivatives
MXPA04004714A (es) 2001-11-21 2004-08-19 Upjohn Co Derivados de aril 1,4-pirazina sustituidos.
EP1472245A2 (en) 2002-02-06 2004-11-03 Vertex Pharmaceuticals Incorporated Heteroaryl compounds useful as inhibitors of gsk-3
DE60320957D1 (en) 2002-03-13 2008-06-26 Janssen Pharmaceutica Nv Sulfonylderivate als histone-deacetylase-inhibitoren
GB0206860D0 (en) 2002-03-22 2002-05-01 Glaxo Group Ltd Compounds
TWI319387B (en) 2002-04-05 2010-01-11 Astrazeneca Ab Benzamide derivatives
CA2483306A1 (en) * 2002-04-23 2003-11-06 Shionogi & Co., Ltd. Pyrazolo[1,5-a]pyrimidine derivative and nad(p)h oxidase inhibitor containing the same
GB0209715D0 (en) 2002-04-27 2002-06-05 Astrazeneca Ab Chemical compounds
US7704995B2 (en) 2002-05-03 2010-04-27 Exelixis, Inc. Protein kinase modulators and methods of use
AU2003234464B2 (en) 2002-05-03 2009-06-04 Exelixis, Inc. Protein kinase modulators and methods of use
EP1510516A4 (en) 2002-05-31 2005-11-02 Eisai Co Ltd PYRAZOL COMPOUND AND MEDICAL COMPOSITION CONTAINING THEM
DE60319820T2 (de) 2002-06-04 2009-03-26 Schering Corp. Pyrazoloä1,5-aüpyrimidin-verbindungen als antivirale agentien
US7449488B2 (en) 2002-06-04 2008-11-11 Schering Corporation Pyrazolopyrimidines as protein kinase inhibitors
WO2004000318A2 (en) 2002-06-21 2003-12-31 Cellular Genomics, Inc. Certain amino-substituted monocycles as kinase modulators
US8673924B2 (en) 2002-09-04 2014-03-18 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
US7196092B2 (en) 2002-09-04 2007-03-27 Schering Corporation N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7196078B2 (en) 2002-09-04 2007-03-27 Schering Corpoartion Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
US8580782B2 (en) 2002-09-04 2013-11-12 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
KR20050033659A (ko) 2002-09-04 2005-04-12 쉐링 코포레이션 사이클린 의존성 키나제 억제제로서의 피라졸로[1,5-ａ]피리미딘 화합물
JP4881558B2 (ja) 2002-09-04 2012-02-22 シェーリング コーポレイション サイクリン依存性キナーゼインヒビターとしてのピラゾロピリミジン
NZ539162A (en) 2002-09-04 2006-07-28 Schering Corp Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7563798B2 (en) 2002-09-04 2009-07-21 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
US7601724B2 (en) 2002-09-04 2009-10-13 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
US7119200B2 (en) 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
NZ539164A (en) 2002-09-04 2006-04-28 Schering Corp Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7205308B2 (en) 2002-09-04 2007-04-17 Schering Corporation Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors
WO2004033431A2 (en) 2002-10-04 2004-04-22 Arena Pharmaceuticals, Inc. Hydroxypyrazoles for use against metabolic-related disorders
US7550470B2 (en) 2002-12-11 2009-06-23 Merck & Co. Inc. Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors
SE0203754D0 (sv) 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
SE0203752D0 (sv) 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
MEP52808A (en) 2003-02-26 2011-05-10 Sugen Inc Aminoheteroaryl compounds as protein kinase inhibitors
US7557110B2 (en) 2003-02-28 2009-07-07 Teijin Pharma Limited Pyrazolo[1,5-A] pyrimidine derivatives
ATE402929T1 (de) 2003-03-11 2008-08-15 Pfizer Prod Inc Pyrazinverbindungen als inhibitoren des transforming growth factor (tgf)
JP2006520794A (ja) 2003-03-21 2006-09-14 スミスクライン ビーチャム コーポレーション 化合物
CN1791580A (zh) 2003-03-24 2006-06-21 麦克公司 联芳基取代的6元杂环钠通道阻滞剂
GB2400101A (en) 2003-03-28 2004-10-06 Biofocus Discovery Ltd Compounds capable of binding to the active site of protein kinases
EP1625123A4 (en) 2003-05-15 2007-08-29 Merck & Co Inc 3- (2-AMINO-1-AZACYCLYL) -5-ARYL-1,2,4-OXADIAZOLE AS S1P RECEPTOR AGONISTS
TWI339206B (en) 2003-09-04 2011-03-21 Vertex Pharma Compositions useful as inhibitors of protein kinases
KR20060070572A (ko) 2003-09-18 2006-06-23 콘포마 세러퓨틱스 코포레이션 Ｈｓｐ90-저해제로서의 신규 헤테로시클릭 화합물
WO2005034952A2 (en) 2003-10-07 2005-04-21 The Feinstein Institute For Medical Research Isoxazole and isothiazole compounds useful in the treatment of inflammation
PL1689233T3 (pl) 2003-11-19 2012-11-30 Array Biopharma Inc Bicykliczne inhibitory MEK
DE10356579A1 (de) 2003-12-04 2005-07-07 Merck Patent Gmbh Aminderivate
US20070149547A1 (en) 2004-02-12 2007-06-28 Celine Bonnefous Bipyridyl amides as modulators of metabotropic glutamate receptor-5
EP1720879A2 (de) 2004-02-25 2006-11-15 Basf Aktiengesellschaft Azolopyrimidin-verbindungen und ihre verwendung zur bekämpfung von schadpilzen
AU2005249380C1 (en) 2004-04-23 2012-09-20 Exelixis, Inc. Kinase modulators and methods of use
US20080153869A1 (en) 2004-06-14 2008-06-26 Bressi Jerome C Kinase Inhibitors
EP1778687A2 (en) 2004-07-27 2007-05-02 SGX Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
US7626021B2 (en) 2004-07-27 2009-12-01 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
ES2354824T3 (es) 2004-11-04 2011-03-18 Vertex Pharmaceuticals, Inc. Pirazolo[1,5-a]pirimidinas útiles como inhibidores de proteínas cinasas.
US8003806B2 (en) 2004-11-12 2011-08-23 OSI Pharmaceuticals, LLC Integrin antagonists useful as anticancer agents
RU2394825C2 (ru) 2004-11-22 2010-07-20 Вертекс Фармасьютикалз Инкорпорейтед Пирролопиразины, пригодные в качестве ингибиторов киназы аврора а
GB0428235D0 (en) 2004-12-23 2005-01-26 Glaxo Group Ltd Novel compounds
BRPI0519508A2 (pt) 2004-12-27 2009-03-17 Alcon Inc análogos de aminopirazina para tratamento de glaucoma e outras doenças ou condições mediadas por rho cinase
US7635699B2 (en) 2004-12-29 2009-12-22 Bristol-Myers Squibb Company Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
GB0500492D0 (en) 2005-01-11 2005-02-16 Cyclacel Ltd Compound
US20060156482A1 (en) 2005-01-14 2006-07-20 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
US7622583B2 (en) 2005-01-14 2009-11-24 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2
GB0501999D0 (en) 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
PE20061093A1 (es) 2005-02-16 2006-11-10 Schering Corp Piperazinas sustituidas con heterociclos con actividad antagonista de cxcr3
DE102005007534A1 (de) 2005-02-17 2006-08-31 Bayer Cropscience Ag Pyrazolopyrimidine
JP5033119B2 (ja) 2005-04-25 2012-09-26 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング キナーゼ阻害剤としての新規アザ複素環化合物
US20070155738A1 (en) 2005-05-20 2007-07-05 Alantos Pharmaceuticals, Inc. Heterobicyclic metalloprotease inhibitors
BRPI0609802A2 (pt) 2005-05-20 2017-05-02 Alantos Pharmaceuticals Holding Inc composto, composição farmacêutica e uso de um composto
US20070155737A1 (en) 2005-05-20 2007-07-05 Alantos Pharmaceuticals, Inc. Heterobicyclic metalloprotease inhibitors
WO2007015632A1 (en) 2005-08-04 2007-02-08 Cgk Co., Ltd. Atm and atr inhibitor
NZ567151A (en) 2005-10-06 2012-03-30 Schering Corp Pyrazolo [1,5 -A] pyrimidine derivatives and their use for inhibiting Checkpoint kinases
RU2008117298A (ru) 2005-10-06 2009-11-20 Шеринг Корпорейшн (US) Пиразолопиримидины как ингибиторы протеинкиназ
AR055206A1 (es) 2005-10-06 2007-08-08 Schering Corp Pirazolo[1, 5 - a]pirimidinas como inhibidoras de proteina quinasa, composiciones farmaceuticas y combinaciones con agentes citostaticos que las comprenden y su uso en la fabricacion de un medicamento para el tratamiento del cancer.
TW200745128A (en) 2005-10-06 2007-12-16 Schering Corp Pyrazolopyrimidines as protein kinase inhibitors
JP5119157B2 (ja) 2005-10-21 2013-01-16 エクセリクシス， インク． カゼインキナーゼｉｉ（ｃｋ２）モジュレーターとしてのピラゾロ−ピリミジン類
EP1945220A1 (en) 2005-10-21 2008-07-23 Mitsubishi Tanabe Pharma Corporation Pyrazolo[1,5-a]pyrimidine compounds as cannabinoid receptor antagonists
AR056786A1 (es) 2005-11-10 2007-10-24 Smithkline Beecham Corp Compuesto de 1h- imidazo ( 4,5-c) piridin-2-ilo, composicion farmaceutica que lo comprende, procedimiento para preparar dicha composicion, su uso para preparar unmedicamento, uso de una combinacion que omprende al compuesto y al menos un agente antineoplasico para preparar un medicamento y dicha com
RU2396269C2 (ru) 2005-12-01 2010-08-10 Ф.Хоффманн-Ля Рош Аг Производные гетероарилзамещенного пиперидина в качестве ингибиторов печеночной карнитин пальмитоилтрансферазы (l-cpt1)
EP1970377A4 (en) 2005-12-09 2013-02-27 Meiji Seika Kaisha LINCOMYCIN DERIVATIVE AND ANTIBACTERIAL AGENT CONTAINING THIS AS AN ACTIVE SUBSTANCE
US7655662B2 (en) 2005-12-22 2010-02-02 Alcon Research, Ltd. (Indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)-pyrazines for treating glaucoma and controlling intraocular pressure
ITMI20060311A1 (it) 2006-02-21 2007-08-22 Btsr Int Spa Dispositivo perfezionato di alimentazione di filo o filatio ad una macchina tessile e metodo per attuare tale alimentazione
GB0603684D0 (en) 2006-02-23 2006-04-05 Novartis Ag Organic compounds
WO2007096764A2 (en) 2006-02-27 2007-08-30 Glenmark Pharmaceuticals S.A. Bicyclic heteroaryl derivatives as cannabinoid receptor modulators
TW200800203A (en) 2006-03-08 2008-01-01 Astrazeneca Ab New use
AU2007231577B2 (en) 2006-03-22 2012-07-19 Vertex Pharmaceuticals Incorporated c-MET protein kinase inhibitors for the treatment of proliferative disorders
EP2007373A4 (en) 2006-03-29 2012-12-19 Foldrx Pharmaceuticals Inc INHIBITION OF ALPHA SYNUCLEINE TOXICITY
WO2007126964A2 (en) 2006-03-31 2007-11-08 Schering Corporation Kinase inhibitors
AU2007268083A1 (en) 2006-05-22 2007-12-06 Schering Corporation Pyrazolo [1, 5-A] pyrimidines as CDK inhibitors
US20080039450A1 (en) 2006-06-22 2008-02-14 Jensen Annika J Compounds
CA2655857C (en) 2006-06-22 2014-12-02 Mallinckrodt Inc. Pyrazine derivatives with extended conjugation and uses thereof
AR061793A1 (es) 2006-07-05 2008-09-24 Mitsubishi Tanabe Pharma Corp Compuesto de pirazolo[1,5-a] pirimidina y composicion farmaceutica
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
PE20121506A1 (es) 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met
US8198448B2 (en) 2006-07-14 2012-06-12 Amgen Inc. Fused heterocyclic derivatives and methods of use
KR20090073121A (ko) 2006-09-29 2009-07-02 노파르티스 아게 Ｐｉ3ｋ 지질 키나제 억제제로서의 피라졸로피리미딘
GB0619342D0 (en) 2006-09-30 2006-11-08 Vernalis R&D Ltd New chemical compounds
EP2450350A1 (en) 2006-10-04 2012-05-09 F. Hoffmann-La Roche AG 3-Pyridinecarboxamide and 2-pyrazinecarboxamide derivatives as HDL-cholesterol raising agents
MX337906B (es) 2006-10-19 2016-03-28 Signal Pharm Llc Compuestos de heteroarilo, composiciones de los mismos, y su uso como inhibidores de proteina cinasas.
WO2008060907A2 (en) 2006-11-10 2008-05-22 Bristol-Myers Squibb Company Pyrrolo-pyridine kinase inhibitors
WO2008063671A2 (en) 2006-11-20 2008-05-29 Alantos Pharmaceuticals Holding, Inc. Heterobicyclic metalloprotease inhibitors
EP2125808A2 (en) 2006-12-15 2009-12-02 Bayer Schering Pharma Aktiengesellschaft 3-h-pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
CA2672438A1 (en) 2006-12-20 2008-07-03 Amgen Inc. Substituted heterocycles and methods of use
GB0625659D0 (en) 2006-12-21 2007-01-31 Cancer Rec Tech Ltd Therapeutic compounds and their use
PE20121126A1 (es) 2006-12-21 2012-08-24 Plexxikon Inc Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa
JP2010519204A (ja) 2007-02-16 2010-06-03 アムジエン・インコーポレーテツド 窒素含有複素環ケトン類およびそれらのｃ−Ｍｅｔ阻害薬としての使用
ES2431163T3 (es) 2007-03-01 2013-11-25 Novartis Ag Inhibidores de PIM quinasa y métodos para su uso
US8372867B2 (en) 2007-04-10 2013-02-12 Bayer Cropscience Ag Insecticidal aryl isoxazoline derivatives
JP2010526823A (ja) 2007-05-10 2010-08-05 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｐｉ３キナーゼ阻害物質としてのキノキサリン誘導体
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
EP2014661A1 (de) 2007-06-13 2009-01-14 Bayer CropScience AG Heterocyclisch substituierte Heterocyclyl-carbonsäurederivate
UY31137A1 (es) 2007-06-14 2009-01-05 Smithkline Beecham Corp Derivados de quinazolina como inhibidores de la pi3 quinasa
US20100190980A1 (en) 2007-06-21 2010-07-29 Taisho Pharmaceutical Co., Ltd Pyrazinamide compound
WO2009002964A1 (en) 2007-06-26 2008-12-31 Lexicon Pharmaceuticals, Inc. Methods of treating serotonin-mediated diseases and disorders
WO2009006580A1 (en) 2007-07-05 2009-01-08 Cv Therapeutics, Inc. Optionally condensed dihydropyridine, dihydropyrimidine and dihydropyrane derivatives acting as late sodium channel blockers
US20090012103A1 (en) 2007-07-05 2009-01-08 Matthew Abelman Substituted heterocyclic compounds
GB0713259D0 (en) 2007-07-09 2007-08-15 Astrazeneca Ab Pyrazine derivatives 954
RU2474580C2 (ru) 2007-07-19 2013-02-10 Шеринг Корпорейшн Гетероциклические амидные соединения как ингибиторы протеинкиназ
CN104844578B (zh) 2007-07-19 2018-06-19 H.隆德贝克有限公司 5元杂环酰胺及相关的化合物
EP2183243A2 (en) 2007-08-01 2010-05-12 Pfizer Inc. Pyrazole compounds and their use as raf inhibitors
WO2009017954A1 (en) 2007-08-01 2009-02-05 Phenomix Corporation Inhibitors of jak2 kinase
WO2009024825A1 (en) 2007-08-21 2009-02-26 Astrazeneca Ab 2-pyrazinylbenzimidazole derivatives as receptor tyrosine kinase inhibitors
WO2009037247A1 (en) 2007-09-17 2009-03-26 Neurosearch A/S Pyrazine derivatives and their use as potassium channel modulators
KR20100089090A (ko) 2007-10-25 2010-08-11 아스트라제네카 아베 세포 증식 장애의 치료에 유용한 피리딘 및 피라진 유도체
MX2010005950A (es) 2007-11-28 2010-06-17 Schering Corp 2-fluoropirazolo[1,5-a]pirimidinas como inhibidores de proteina quinasa.
WO2009075790A1 (en) 2007-12-07 2009-06-18 Alantos Pharmaceuticals Holding, Inc. Metalloprotease inhibitors for intra-articular application
CN101932583A (zh) * 2007-12-19 2010-12-29 沃泰克斯药物股份有限公司 用作JAK2抑制剂的吡唑并[1,5-a]嘧啶类
MY172151A (en) 2008-01-04 2019-11-14 Intellikine Llc Certain chemical entities, compositions and methods
EP2085398A1 (en) 2008-02-01 2009-08-05 Merz Pharma GmbH & Co. KGaA Pyrazolopyrimidines, a process for their preparation and their use as medicine
WO2009106443A1 (en) 2008-02-25 2009-09-03 F. Hoffmann-La Roche Ag Pyrrolopyrazine kinase inhibitors
CA2713718A1 (en) 2008-02-25 2009-09-03 F. Hoffmann-La Roche Ag Pyrrolopyrazine kinase inhibitors
EP2247592B1 (en) 2008-02-25 2011-08-31 F. Hoffmann-La Roche AG Pyrrolopyrazine kinase inhibitors
EP2247595B1 (en) 2008-02-25 2011-07-20 F. Hoffmann-La Roche AG Pyrrolopyrazine kinase inhibitors
TW200940537A (en) 2008-02-26 2009-10-01 Astrazeneca Ab Heterocyclic urea derivatives and methods of use thereof
WO2009117157A1 (en) 2008-03-20 2009-09-24 Amgen Inc. Aurora kinase modulators and method of use
WO2009152087A1 (en) 2008-06-10 2009-12-17 Plexxikon, Inc. Bicyclic heteroaryl compounds and methods for kinase modulation, and indications therefor
JP5788316B2 (ja) 2008-07-08 2015-09-30 インテリカイン， エルエルシー キナーゼインヒビターおよび使用方法
AU2009279936A1 (en) 2008-08-05 2010-02-11 Banyu Pharmaceutical Co., Ltd. Therapeutic compounds
GB0814364D0 (en) 2008-08-05 2008-09-10 Eisai London Res Lab Ltd Diazaindole derivatives and their use in the inhibition of c-Jun N-terminal kinase
CN102223798A (zh) 2008-09-24 2011-10-19 巴斯夫欧洲公司 用于防治无脊椎动物害虫的吡唑化合物
CN102317277A (zh) 2008-10-21 2012-01-11 沃泰克斯药物股份有限公司 C-met蛋白激酶抑制剂
PE20110828A1 (es) 2008-10-31 2011-11-22 Genentech Inc Compuestos de pirazolopirimidina como inhibidores de jak
KR101712576B1 (ko) 2008-11-10 2017-03-06 버텍스 파마슈티칼스 인코포레이티드 Ａｔｒ 키나제의 억제제로서 유용한 화합물
WO2010059836A1 (en) 2008-11-20 2010-05-27 Decode Genetics Ehf Substituted aza-bridged bicyclics for cardiovascular and cns disease
AU2009324894B2 (en) 2008-11-25 2015-04-09 University Of Rochester MLK inhibitors and methods of use
SG171956A1 (en) 2008-12-05 2011-07-28 Hoffmann La Roche Pyrrolopyrazinyl urea kinase inhibitors
HRP20220581T1 (hr) 2008-12-19 2022-06-10 Vertex Pharmaceuticals Incorporated Spojevi korisni kao inhibitori atr kinaze
ES2567047T3 (es) 2008-12-23 2016-04-19 Abbvie Inc. Derivados de pirimidina anti-virales
WO2010086040A1 (en) 2009-01-29 2010-08-05 Biomarin Iga, Ltd. Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy
MX2011008059A (es) 2009-01-30 2011-10-11 Toyama Chemical Co Ltd Derivado del acido n-acil antranilico o sal del mismo.
US20100204265A1 (en) 2009-02-09 2010-08-12 Genelabs Technologies, Inc. Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections
JP2012517471A (ja) 2009-02-11 2012-08-02 スノビオン プハルマセウトイカルス インコーポレイテッド ヒスタミンｈ３インバースアゴニスト及びアンタゴニスト、並びにその使用方法
CN101537007A (zh) 2009-03-18 2009-09-23 中国医学科学院血液病医院（血液学研究所） N-(噻吩-2)吡唑并[1,5-a]嘧啶-3-甲酰胺类化合物在制备抗恶性肿瘤药物方面的应用
US20120065247A1 (en) 2009-03-27 2012-03-15 Discoverybiomed, Inc. Modulating ires-mediated translation
UA110324C2 (en) 2009-07-02 2015-12-25 Genentech Inc Jak inhibitory compounds based on pyrazolo pyrimidine
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
CA2767091A1 (en) 2009-07-15 2011-01-20 Abbott Laboratories Pyrrolopyrazine inhibitors of kinases
EA026693B1 (ru) 2009-08-17 2017-05-31 Интелликайн ЭлЭлСи Производные бензоксазола и бензотиазола в качестве ингибиторов pi3-киназы
US8669259B2 (en) 2009-08-26 2014-03-11 Merck Sharp & Dohme Corp. Heterocyclic amide compounds as protein kinase inhibitors
CN101671336B (zh) 2009-09-23 2013-11-13 辽宁利锋科技开发有限公司 芳杂环并嘧啶衍生物和类似物及其制备方法和用途
EP2509602B9 (en) 2009-12-04 2017-11-01 Senhwa Biosciences, Inc. Pyrazolopyrimidines and related heterocycles as ck2 inhibitors
GB2550698B (en) 2009-12-22 2018-04-11 Intel Corp Method and Apparatus to provide secure application execution
ES2572387T3 (es) 2010-03-18 2016-05-31 Pasteur Institut Korea Compuestos anti-infecciosos
US8518945B2 (en) 2010-03-22 2013-08-27 Hoffmann-La Roche Inc. Pyrrolopyrazine kinase inhibitors
WO2011121096A1 (en) 2010-03-31 2011-10-06 Dkfz Deutsches Krebsforschungszentrum PYRAZOL[1,5-a]PYRIMIDINE DERIVATIVES AS WNT PATHWAY ANTAGONISTS
AU2011236510A1 (en) 2010-04-08 2012-10-11 Zoetis Llc Substituted 3,5- di phenyl - isoxazoline derivatives as insecticides and acaricides
US20130030237A1 (en) 2010-04-15 2013-01-31 Charles Theuer Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitors
EP2569287B1 (en) 2010-05-12 2014-07-09 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
US8969356B2 (en) 2010-05-12 2015-03-03 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
WO2011143419A1 (en) 2010-05-12 2011-11-17 Vertex Pharmaceuticals Incorporated Pyrazines useful as inhibitors of atr kinase
JP2013529200A (ja) 2010-05-12 2013-07-18 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用な化合物
US9096584B2 (en) 2010-05-12 2015-08-04 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
SG185524A1 (en) 2010-05-12 2012-12-28 Vertex Pharma Compounds useful as inhibitors of atr kinase
KR20130083387A (ko) 2010-05-20 2013-07-22 에프. 호프만-라 로슈 아게 Syk 및 jak 억제제로서 피롤로피라진 유도체
RU2012152352A (ru) 2010-05-20 2014-06-27 Ф. Хоффманн-Ля Рош Аг ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-b]ПИРАЗИН-7-КАРБОКСАМИДА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ JAK И SYK
MX2013000103A (es) 2010-06-23 2013-06-13 Vertex Pharma Derivados de pirrolo-pirazina utiles como inhibidores de cinasa art.
MX2012015292A (es) 2010-06-24 2013-05-30 Gilead Sciences Inc Pirazolo[1, 5]pirimidinas en la forma de agentes antivirales.
CN102311396B (zh) 2010-07-05 2015-01-07 暨南大学 一种吡嗪类衍生物和其制备方法及在制药中的应用
RU2604062C2 (ru) 2010-07-13 2016-12-10 Ф.Хоффманн-Ля Рош Аг ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНА И ТИЕНО[3,2-b]ПИРИМИДИНА В КАЧЕСТВЕ МОДУЛЯТОРОВ IRAK-4
EP2407478A1 (en) 2010-07-14 2012-01-18 GENETADI Biotech, S.L. New cyclotetrapeptides with pro-angiogenic properties
WO2012022045A1 (en) 2010-08-20 2012-02-23 Hutchison Medipharma Limited Pyrrolopyrimidine compounds and uses thereof
EP2608669B1 (en) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
WO2012067822A1 (en) 2010-11-16 2012-05-24 Abbott Laboratories Pyrazolo [1, 5 -a] pyrimidin potassium channel modulators
US9370567B2 (en) 2010-11-16 2016-06-21 Array Biopharma Inc. Combination of checkpoint kinase 1 inhibitors and WEE 1 kinase inhibitors
MX385600B (es) 2010-12-08 2025-03-18 Us Health Pirazolopirimidinas sustituidas como activadores de la glucocerebrosidasa.
CA2825098C (en) 2011-01-27 2020-03-10 Universite De Montreal Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators
MX2013011450A (es) * 2011-04-05 2014-02-03 Vertex Pharma Compuestos de aminopirazina utiles como inhibidores de la cinasa ataxia telangiectasia mutada y rad3 relacionados (atr).
US9029389B2 (en) 2011-04-21 2015-05-12 Institut Pasteur Korea Anti-inflammation compounds
JP6005134B2 (ja) 2011-04-21 2016-10-12 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ フルオロアルキル置換ピラゾロピリジンおよびその使用
AU2012255792A1 (en) 2011-05-17 2013-11-07 Principia Biopharma Inc. Azaindole derivatives as tyrosine kinase inhibitors
JP6061922B2 (ja) 2011-06-22 2017-01-18 ザ ジェネラル ホスピタル コーポレイション プロテイノパチーの処置方法
WO2012178125A1 (en) 2011-06-22 2012-12-27 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
JP2014520161A (ja) 2011-06-22 2014-08-21 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用な化合物
JP2014522818A (ja) 2011-06-22 2014-09-08 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用な化合物
AU2012283775A1 (en) 2011-07-13 2014-01-23 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase
WO2013052263A2 (en) 2011-09-16 2013-04-11 Microbiotix, Inc. Antifungal compounds
EP2751097A2 (en) 2011-09-30 2014-07-09 Vertex Pharmaceuticals Incorporated Processes for making compounds useful as inhibitors of atr kinase
JP2014528419A (ja) 2011-09-30 2014-10-27 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼ阻害剤として有用な化合物
US8853217B2 (en) 2011-09-30 2014-10-07 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
EP2751088B1 (en) 2011-09-30 2016-04-13 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
CN103957917A (zh) 2011-09-30 2014-07-30 沃泰克斯药物股份有限公司 用atr抑制剂治疗胰腺癌和非小细胞肺癌
JP6073343B2 (ja) 2011-10-20 2017-02-01 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ サーチュイン調節因子としての置換された二環式アザ複素環およびアナログ
EP2776421A1 (en) 2011-11-09 2014-09-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
US8841337B2 (en) 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
WO2013071094A1 (en) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
WO2013071093A1 (en) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Pyrazine compounds useful as inhibitors of atr kinase
JP2015502925A (ja) 2011-11-09 2015-01-29 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼの阻害剤として有用なピラジン化合物
US9193725B2 (en) 2012-03-14 2015-11-24 Bristol-Meyers Squibb Company Cyclic hydrazine derivatives as HIV attachment inhibitors
CN108553467A (zh) 2012-04-02 2018-09-21 赛特凯恩蒂克公司 改善膈肌功能的方法
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
NZ726671A (en) 2012-04-05 2018-04-27 Vertex Pharma Compounds useful as inhibitors of atr kinase and combination therapies thereof
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN103373996A (zh) 2012-04-20 2013-10-30 山东亨利医药科技有限责任公司 作为crth2受体拮抗剂的二并环衍生物
EP3210980B1 (en) 2012-05-15 2024-04-03 Cancer Research Technology Ltd Process for manufacturing 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)- 2-pyridyl]amino]pyrazine-2-carbonitrile
RU2014143250A (ru) 2012-05-23 2016-07-20 Савира Фармасьютикалз Гмбх Производные 7-оксо-тиазолопиридин карбоновой кислоты и их применение при лечении, облегчении или профилактике вирусного заболевания
US20130317021A1 (en) 2012-05-23 2013-11-28 Savira Pharmaceuticals Gmbh Heterocyclic pyrimidine carbonic acid derivatives which are useful in the treatment, amelioration or prevention of a viral disease
US20140018361A1 (en) 2012-07-11 2014-01-16 Nimbus Iris, Inc. Irak inhibitors and uses thereof
WO2014015523A1 (en) 2012-07-27 2014-01-30 Hutchison Medipharma Limited Novel heteroaryl and heterocycle compounds, compositions and methods
CN104619699A (zh) 2012-08-06 2015-05-13 萨维拉制药有限公司 二羟基嘧啶碳酸衍生物以及它们在治疗、改善或预防病毒疾病中的用途
ES2616432T3 (es) 2012-08-09 2017-06-13 VIIV Healthcare UK (No.5) Limited Derivados de alquenos tricíclicos como inhibidores de la unión del VIH
ES2616492T3 (es) 2012-08-09 2017-06-13 VIIV Healthcare UK (No.5) Limited Derivados de piperidina amida como inhibidores de la fijación del VIH
ES2614034T3 (es) 2012-08-09 2017-05-29 VIIV Healthcare UK (No.5) Limited Derivados de amidina tricíclica como inhibidores de la unión del VIH
MX2015001897A (es) 2012-08-17 2015-05-11 Bayer Cropscience Ag Azaindolcarboxamidas y azaindoltiocarboxamidas como insecticidas y acaricidas.
JP6258937B2 (ja) 2012-08-24 2018-01-10 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 新規二環式ピリジン誘導体
WO2014035140A2 (en) 2012-08-30 2014-03-06 Kainos Medicine, Inc. Compounds and compositions for modulating histone methyltransferase activity
WO2014039831A1 (en) 2012-09-07 2014-03-13 Takeda Pharmaceutical Company Limited SUBSTITUTED-1,4-DIHYDROPYRAZOLO[4,3-b]INDOLES
WO2014042433A2 (en) 2012-09-14 2014-03-20 Kainos Medicine, Inc. Compounds and compositions for modulating adenosine a3 receptor activity
TW201412740A (zh) 2012-09-20 2014-04-01 Bayer Pharma AG 經取代之吡咯并嘧啶胺基苯并噻唑酮
US9688635B2 (en) 2012-09-24 2017-06-27 Neupharma, Inc. Certain chemical entities, compositions, and methods
US8999632B2 (en) 2012-10-04 2015-04-07 Vertex Pharmaceuticals Incorporated Method for measuring ATR inhibition mediated increases in DNA damage
CN104870452B (zh) 2012-10-22 2018-04-13 希望之城 Etp衍生物
AU2013334635B2 (en) 2012-10-24 2018-12-06 Becton, Dickinson And Company Hydroxamate substituted azaindoline-cyanine dyes and bioconjugates of the same
RS57210B1 (sr) * 2012-12-07 2018-07-31 Vertex Pharmaceuticals Inncorporated 2-amino-6-fluoro-n-(5-fluoro-4-(4-(4-(oksetan-3-il)piperazin-1-karbonil)piperidin-1-il)piridin-3-il)pirazolo[1,5alfa]pirimidin-3-karboksamid kao inhibitor atr kinaze
JP2016512816A (ja) 2013-03-15 2016-05-09 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼの阻害剤として有用な化合物
US8957078B2 (en) 2013-03-15 2015-02-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
EP2970286A1 (en) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Inc. Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
US20150158868A1 (en) 2013-12-06 2015-06-11 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
RU2720408C2 (ru) 2013-12-06 2020-04-29 Вертекс Фармасьютикалз Инкорпорейтед Способ получения ингибиторов atr киназы (варианты)
ES2777608T3 (es) 2014-06-05 2020-08-05 Vertex Pharma Derivados radiomarcados de un compuesto de 2-amino-6-fluoro-N-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida útiles como inhibidores de ATR cinasa, la preparación de dicho compuesto y diferentes formas sólidas del mismo
NZ727399A (en) 2014-06-17 2022-07-29 Vertex Pharma Method for treating cancer using a combination of chk1 and atr inhibitors

Also Published As

Publication number Publication date
HUE052808T2 (hu) 2021-05-28
AU2013355124A1 (en) 2015-06-18
RS64234B1 (sr) 2023-06-30
WO2014089379A9 (en) 2015-01-15
JP6574859B2 (ja) 2019-09-11
HRP20211034T1 (hr) 2021-12-10
PT3486245T (pt) 2021-07-30
EP4534538A2 (en) 2025-04-09
HK1209746A1 (en) 2016-04-08
ES2842876T3 (es) 2021-07-15
SI3486245T1 (sl) 2021-09-30
CY1124291T1 (el) 2022-07-22
LT2941432T (lt) 2018-06-11
AU2018204431A1 (en) 2018-07-05
RU2689996C2 (ru) 2019-05-30
IL239218A0 (en) 2015-07-30
SI2941432T1 (en) 2018-07-31
SMT201800279T1 (it) 2018-07-17
SG10201606373XA (en) 2016-09-29
ME03036B (me) 2018-10-20
ZA201503871B (en) 2016-11-30
US20140249157A1 (en) 2014-09-04
RU2015127079A (ru) 2017-01-10
ZA201605990B (en) 2019-12-18
AU2018204431B2 (en) 2020-04-02
BR112015012454B1 (pt) 2022-07-05
HUE061909T2 (hu) 2023-08-28
US20180072735A1 (en) 2018-03-15
CN107501275A (zh) 2017-12-22
ES2669423T3 (es) 2018-05-25
HRP20202058T1 (hr) 2021-02-19
TWI618706B (zh) 2018-03-21
PT2941432T (pt) 2018-06-01
SMT202100425T1 (it) 2021-09-14
CY1126044T1 (el) 2023-11-15
EP4190786A1 (en) 2023-06-07
CN107501275B (zh) 2019-11-22
NZ731337A (en) 2019-02-22
JP2016501244A (ja) 2016-01-18
CN107501274A (zh) 2017-12-22
US20200140441A1 (en) 2020-05-07
US11370798B2 (en) 2022-06-28
HRP20230476T1 (hr) 2023-07-21
DK3418281T3 (da) 2020-12-07
KR20150091171A (ko) 2015-08-07
LT3486245T (lt) 2021-08-25
WO2014089379A1 (en) 2014-06-12
RS62174B1 (sr) 2021-08-31
CN107629059B (zh) 2020-07-28
US9340546B2 (en) 2016-05-17
BR112015012454A2 (pt) 2017-07-11
CA2892608C (en) 2021-10-19
SG11201504467YA (en) 2015-07-30
US9718827B2 (en) 2017-08-01
ES2884030T3 (es) 2021-12-10
US20140163000A1 (en) 2014-06-12
MX368042B (es) 2019-09-17
EP3808749A1 (en) 2021-04-21
EP4190786B1 (en) 2025-02-26
US12187731B2 (en) 2025-01-07
MX2015007101A (es) 2015-09-29
ES2946360T3 (es) 2023-07-17
HUE055618T2 (hu) 2021-12-28
SMT202000713T1 (it) 2021-03-15
EP3418281B1 (en) 2020-09-30
US20230271963A1 (en) 2023-08-31
JP6401709B2 (ja) 2018-10-10
SMT202300157T1 (it) 2023-07-20
EP2941432B8 (en) 2018-06-27
RS57210B1 (sr) 2018-07-31
EP3418281A1 (en) 2018-12-26
SI3418281T1 (sl) 2021-02-26
TW201434839A (zh) 2014-09-16
RS61319B1 (sr) 2021-02-26
US11117900B2 (en) 2021-09-14
US10392391B2 (en) 2019-08-27
DK2941432T3 (en) 2018-06-14
DK3486245T3 (da) 2021-07-19
PL3808749T3 (pl) 2023-07-10
FI3808749T3 (fi) 2023-05-31
LT3418281T (lt) 2021-01-11
CN107629059A (zh) 2018-01-26
CA2892608A1 (en) 2014-06-12
BR112015012454A8 (pt) 2019-10-01
AU2013355124B2 (en) 2018-03-22
DK3808749T3 (da) 2023-06-06
LT3808749T (lt) 2023-06-12
TR201807740T4 (tr) 2018-06-21
IL263262B (en) 2019-07-31
KR102213986B1 (ko) 2021-02-09
US10787452B2 (en) 2020-09-29
HK1217190A1 (zh) 2016-12-30
US9650381B2 (en) 2017-05-16
PL2941432T3 (pl) 2018-09-28
US20210047333A1 (en) 2021-02-18
HRP20180859T1 (hr) 2018-07-13
PL3486245T3 (pl) 2021-11-08
EP3808749B1 (en) 2023-03-08
HUE037371T2 (hu) 2018-08-28
EP3486245A1 (en) 2019-05-22
EP3486245B1 (en) 2021-04-28
CN104903325A (zh) 2015-09-09
PT3418281T (pt) 2020-12-30
EP2941432B1 (en) 2018-03-07
NZ630457A (en) 2017-05-26
EP2941432A1 (en) 2015-11-11
SI3808749T1 (sl) 2023-07-31
PT3808749T (pt) 2023-06-07
US20160347754A1 (en) 2016-12-01
IL263262A (en) 2018-12-31
JP2018087213A (ja) 2018-06-07
CN104903325B (zh) 2017-10-20
CN107501274B (zh) 2019-11-22
CY1120232T1 (el) 2019-07-10
US20180155346A1 (en) 2018-06-07

Similar Documents

Publication Publication Date Title
CY1123702T1 (el) Πυραζολο[1,5-αλφα]πυριμιδινες χρησιμες ως αναστολεις της κινασης atr για την αντιμετωπιση καρκινικων νοσων
CY1120002T1 (el) Παραγωγα πυραζινης χρησιμα ως αναστολεις κινασης atr
IN2014KN02410A (el)
MX2014003796A (es) Compuestos utiles como inhibidores de la cinasa ataxia telangiectasia mutada y rad3 relacionados (atr).
MX2012013081A (es) Compuestos utiles como inhibidores de cinasa atr.
WO2014143242A8 (en) Compounds useful as inhibitors of atr kinase
MX2012013082A (es) Derivados de 2-aminopiridina utiles como iinhibidores de cinasa atr.
CY1121763T1 (el) Παραγωγα διπυραζολιου ως αναστολεις jak
CY1125613T1 (el) 4-ιμιδαζοπυριδαζιν-1-υλ-βενζαμιδια και 4- ιμιδαζοτριαζιν-1-υλ-βενζαμιδια ως αναστολεις βτκ
CY1122601T1 (el) Αναστολεις gsk3 και μεθοδοι χρησης αυτων
MX2011004953A (es) Compuestos utiles como inhibidores de cinasa atr.
WO2011143423A3 (en) Compounds useful as inhibitors of atr kinase
CY1120734T1 (el) Στερεες μορφες ενος εκλεκτικου αναστολεα cdk4/6
CY1118112T1 (el) Διυποκατεστημενες βενζοθειενυλ-πυρρολοτριαζινες και η χρηση τους ως αναστολεις κινασης υποδοχεα του αυξητικου παραγοντα των ινοβλαστων (fgfr)
WO2011143425A3 (en) Compounds useful as inhibitors of atr kinase
EA201500182A1 (ru) 4-МЕТИЛ-2,3,5,9,9b-ПЕНТААЗАЦИКЛОПЕНТА[a]НАФТАЛИНЫ
CY1116405T1 (el) Ν1/ν2-λακταμικοι αναστολεις ακετυλο-coa καρβοξυλασης
EA201891091A1 (ru) Соединения ингибитора jak киназы для лечения респираторного заболевания
CY1117197T1 (el) Ενωσεις τριαζολοπυριδινης ως αναστολεις της κινασης ριμ
EA201490042A1 (ru) Азетидинил-фенил-, пиридил- или пиразинилкарбоксамидные производные как ингибиторы jak
EA201301183A1 (ru) Гетероциклические соединения в качестве ингибиторов киназ
IN2014KN00929A (el)
CY1116315T1 (el) Παραγωγα κιναζολιν-4(3η)-ονης που χρησιμοποιουνται ως αναστολεις κινασης ρι3
EA201500278A1 (ru) Пиразолилхиназолиновые ингибиторы киназы
CY1117122T1 (el) Παραγωγα πυραζολοσπειροκετονης για χρηση ως αναστολεις ακετyλ-coa καρβοξυλασης